Discovery of 4-Amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin- 3-yl)pyrido[2,3-d]pyrimidine, an Orally Active, Non-Nucleoside Adenosine Kinase Inhibitor

Citations Over TimeTop 20% of 2001 papers

Abstract

Adenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation. Inhibition of adenosine kinase (AK), the primary metabolic enzyme for ADO, selectively increases ADO concentrations at sites of tissue trauma and enhances the analgesic and antiinflammatory actions of ADO. Optimization of the high-throughput screening lead, 4-amino-7-aryl-substituted pteridine (5) (AK IC50 = 440 nM), led to the identification of compound 21 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido [2,3-d]pyrimidine, ABT-702), a novel, potent (AK IC50 = 1.7 nM) non-nucleoside AK inhibitor with oral activity in animal models of pain and inflammation.

Related Papers

• → Differential adenosine uptake in mixed neuronal/glial or purified glial cultures of avian retinal cells: Modulation by adenosine metabolism and the ERK cascade(2011)11 cited
• → S-Adenosylmethionine Metabolism as a Target for Adenosine Toxicity(1986)1 cited
• → Production of adenosine and nucleoside analogs by the exchange reaction catalyzed by rat liver adenosine kinase(1995)2 cited
• → ADENOSINE KINASE OF MAMMALIAN BRAIN: PARTIAL PURIFICATION AND ITS ROLE FOR THE UPTAKE OF ADENOSINE(1972)102 cited
• → ChemInform Abstract: Palladium‐Mediated Synthesis of C‐5 Pyrimidine Nucleoside Thioethers from Disulfides and Mercurinucleosides.(1992)